Stockreport

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depre...

Atai Beckley N.V - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF  Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstr [Read more]